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Abstract: Chronic plaque psoriasis affects more than 2% of world population, has a chronic recurrent 
behavior, gives a heavy burden to the patients’ quality of life, and hence remains a huge medical 
and social problem. The clinical results of conventional therapies of psoriasis are not satisfactory. 
According to the current knowledge of the molecular and cellular basis of psoriasis, it is deﬁ  ned as 
an immune-mediated chronic inﬂ  ammatory and hyperproliferative skin disease. A new generation 
of biological drugs, targeting molecules and cells involved into perturbed pro-inﬂ  ammatory immune 
response in the psoriatic skin and joints, has been recently designed and applied clinically. These 
biological agents are bioengineered proteins such as chimeric and humanized antibodies and fusion 
proteins. In particular, they comprise the antitumor necrosis factor-α agents etanercept, inﬂ  iximab, 
and adalimumab, with clinical efﬁ  cacy in both moderate-severe psoriasis and psoriatic arthritis, and 
the anti-CD11a efalizumab with selective therapeutic action exclusively in the skin. Here, we overview 
recent ﬁ  ndings on the molecular pathways relevant to the inﬂ  ammatory response in psoriasis and 
present our clinical experience with the drugs currently employed in the dermatologic manifestations, 
namely etanercept, inﬂ  iximab, and efalizumab. The growing body of clinical data on the efﬁ  cacy 
and safety of antipsoriasis biological drugs is reviewed as well. Particular focus is given to long-term 
safety concerns and feasibility of combined therapeutic protocols to ameliorate clinical results.
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Introduction
Psoriasis is one of the most common chronic and recurrent dermatoses affecting 
approximately 2% of the general population in Western countries. The incidence of 
psoriasis does not depend on the sex. The disease can affect people of all ages, although 
its onset can occur in early adulthood. Approximately 10%–30% of patients with 
psoriasis develop psoriatic arthritis (PsA). Pretty often, psoriasis is associated with 
systemic disorders such as Crohn’s disease, type 2 diabetes, and metabolic syndrome. 
The association of psoriasis and cardiovascular pathologies represents an emerging 
concern for patients with moderate-severe psoriasis (Grifﬁ  ths and Barker 2007). 
Clinically, psoriasis vulgaris is characterized by well-demarcated erythema and scaly 
skin plaques. The psoriatic lesions often occur at sites of epidermal trauma, such as 
elbows and knees, and are often symmetrical. Morphological features of chronic plaque 
psoriasis include marked increase in keratinocyte proliferation, abnormal pattern of 
keratinocyte differentiation, signiﬁ  cant alterations in dermal capillary vasculature, 
and prominent inﬂ  ammatory cell inﬁ  ltration of both the dermis and epidermis. The 
etiology and pathogenesis of psoriasis remain unclear so far. It is thought that psoriasis 
and associated PsA belong to complex pathologies with both inherited and acquired 
components. There is evidence of familial traits and association of psoriasis with human 
leukocyte antigen (HLA) antigens (Travers 2000). Thorough genome-wide genetic 
analyses of affected families have revealed some susceptibility loci for psoriasis and 
PsA (Valdimarsson 2007). However, corresponding genes still have to be identiﬁ  ed. Biologics: Targets & Therapy 2008:2(4) 688
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Much attention is currently paid to the characterization of 
the single susceptibility genes in order to early diagnose 
and predict severity of this disorder, improve its treatment, 
and eventually prevent its onset (Liu et al 2007). The acquired 
character of psoriasis is conﬁ  rmed by numerous observations 
that its onset is often associated with trauma, stress, bacte-
rial and viral infections, administration of proinﬂ  ammatory 
drugs such as interferons (IFNs), or with rapid withdrawal 
of immunosuppressive drugs, for example, corticosteroids 
(Grifﬁ  ths and Barker 2007). It is generally assumed that 
unbalanced immune responses are major players in the 
disease process. The perturbed immune responses seem to 
contribute to the two major features of the psoriatic skin, per-
sistent inﬂ  ammation and hyperproliferation of keratinocytes 
(Bruch-Gerharz et al 2003). The exact sequence of events, as 
well as the molecular mediators that lead to inﬂ  ammatory and 
hyperproliferative responses are yet to be deﬁ  ned. However, 
both systemic and topical preparations with clinical efﬁ  cacy 
in psoriasis possess immuno-modulating properties with both 
antiinﬂ  ammatory and antiproliferative action.
In the present paper, we will overview the data on the 
pathogenesis of chronic immune-mediated inﬂ  ammation in 
the psoriatic skin, with special emphasis on the molecular 
targets for the recently approved and clinically effective 
biological drugs. The Italian experience of clinical applica-
tion of biological drugs in the patients with moderate/severe 
forms of psoriasis will also be described.
Pathogenesis of chronic 
inﬂ  ammation in the psoriatic skin
The persistence of the psoriatic lesion is currently viewed as 
depending on a vicious proinﬂ  ammatory circuit interactively 
sustained both by resident cell populations of the skin and 
inﬁ  ltrating leukocytes. The latter relies on the relentless 
immune cell-driven expression of a complex system of 
proinﬂ  ammatory cytokines and potent chemoattractants by 
epidermal keratinocytes. This circuit is currently assumed 
as the basic paradigm of T cell-based skin inﬂ  ammation, 
and has been well documented in the active lesion of 
psoriasis (Pastore et al 2006). However, until recently, no 
speciﬁ  c causes for the initiation of this disease were recog-
nized. At a cellular level, the accumulation of inﬂ  ammatory 
cells largely consisting of activated T cells and plasmacytoid 
dendritic cells precedes other microscopic and clinical symp-
toms of the pathology. This observation led to the hypothesis 
of the autoimmune character of psoriasis (Baumgarth and 
Bevins 2007). According to this study, the antimicrobial 
peptide cathelicidin, LL37, which is strongly represented in 
psoriatic lesions (Ong et al 2002), binds to the DNA leaked 
from damaged cells in the lesional epidermis and forms an 
immunogenic complex that breaks tolerance and induces the 
production of IFN-α by plasmacytoid dendritic cells (Lande 
et al 2007). The molecular pathways underlying peculiar 
susceptibility of the psoriatic skin to trigger this reaction, 
including the early and preferential recruitment of plasma-
cytoid dendritic cells, remain elusive so far.
Central role of TNF-α in psoriatic 
inﬂ  ammation
Tumor necrosis factor-α (TNF-α) is crucially involved in 
the pathogenesis of many human diseases, including sepsis, 
cancer and inﬂ  ammatory disorders of the gut, joint, and skin. 
The central role of this cytokine in psoriasis has deﬁ  nitely 
come to light through the observations of the efﬁ  cacy of 
anti-TNF-α biological therapies (Girolomoni et al 2002). 
Virtually all cell types can be induced to express TNF-α, 
although activated dendritic cells, monocytes, macrophages, 
neutrophils, and T cells are by far its richest sources. 
Notably, both IFN-γ-secreting type-1 helper T (Th1) cells 
and interleukin (IL)-4 type-2 helper T- (Th2) cells release 
relevant levels of this potent pro-inﬂ  ammatory cytokine, 
indicating its participation to all T cell-mediated reactions. 
For all T cell subpopulations, TNF-α acts as a major inducer 
of functional maturation. The sequence of events leading 
to the TNF-α-driven inﬂ  ammatory response in the skin is 
schematized in Figure 1. In the early phases of skin response 
to physical and chemical insults, perivascular mast cells 
degranulate, releasing a plethora of presynthesized mediators 
that includes TNF-α (Figure 1A). Mast cell-produced media-
tors trigger fast activation of the endothelial cells, which 
consequently up-regulate adhesion molecules and cytokines 
(Figure 1B). This up-regulation favors leukocyte adherence to 
vascular endothelium, rolling, and extravasation (Figure 1C). 
The activated leukocytes recruited into the skin release huge 
amount of TNF-α. Epidermal keratinocytes themselves are 
modest producers of TNF-α, but they respond to this cyto-
kine with an articulate program of de novo expression and 
release of other pro-inﬂ  ammatory cytokines, chemokines, 
and growth factors (Figure 1D) (Pastore et al 2006). The 
growth factors include vascular endothelial growth factors 
and the angiopoietins responsible of the characteristic abnor-
mal dermal vascular proliferation and angiogenesis (Grifﬁ  ths 
and Barker 2007).
Bioactive TNF-α can be found in two forms, a membrane-
bound form and a proteolytically solubilized form. Its bio-
logical effects are mediated by two cell surface receptors, Biologics: Targets & Therapy 2008:2(4) 689
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respectively. One is the ubiquitously expressed TNF-R1 
(synonyms, p55 and CD120a) and the other one is TNF-R2 
known also as p75 or CD120b. The role of TNF-R1 in skin 
inﬂ  ammation has been conﬁ  rmed experimentally (Pasparakis 
et al 2002). TNF-R2 is predominantly found on hematopoi-
etic and endothelial cells and crucially implicated in the TNF-
α-driven cell apoptosis (Locksley et al 2001). Both soluble 
and membrane-bound forms of TNF-α are the molecular tar-
gets for biological therapy of psoriasis. In particular, the anti-
TNF-α drugs used for the therapy of psoriasis are based either 
on anti-TNF-α monoclonal antibodies such as inﬂ  iximab or 
on TNF-R-based reagents such as etanercept (Gisondi et al 
2004) (Figure 2A). They were ﬁ  rst used for the treatment of 
patients with moderate-to-severe rheumatoid arthritis who 
failed to respond to conventional therapies. Inﬂ  iximab is 
a chimeric anti-TNF-α monoclonal immunoglobulin G1a 
(IgG1a) antibody, with a human constant region and a murine 
variable portion. Inﬂ  iximab binds and neutralizes the soluble 
form of TNF-α with extremely high afﬁ  nity. It also binds 
the membrane-bound form, with lower afﬁ  nity though. Thus, 
by binding to TNF-α, inﬂ  iximab triggers the elimination of 
TNF-α-producing cells by both complement-mediated and 
antibody-dependent, cytotoxic mechanisms. Inﬂ  iximab is 
also currently approved by the United States Food and Drug 
Administration (US FDA) to be used in combination with 
methotrexate for the treatment of active rheumatoid arthritis 
and Crohn’s disease. Etanercept is a genetically engineered 
fusion protein consisting of an homodimer of the extracellular 
portion of TNF-R p75 subunit fused with the constant region 
of human IgG1. The complexes of TNF-α with etanercept 
are quite unstable. Nonetheless, they diminish or even pre-
vent the biological actions of the soluble forms of TNF-α. 
Etanercept is the US FDA-approved drug for the treatment 
of psoriatic arthritis, rheumatoid arthritis, and polyarticular-
course juvenile rheumatoid arthritis. Finally, the genetically 
engineered recombinant human IgG1 monoclonal antibody 
adalimumab, which binds both soluble and membrane-bound 
TNF-α with high afﬁ  nity, is presently limited to the therapy 
of active, progressive psoriatic arthritis that failed to respond 
to one or more antirheumatic drugs.
Psoriasis as a T cell-mediated 
skin disorder
Cytokines of the Th1 pathway, including IFN-γ, IL-2, and 
IL-12 are abundantly expressed in the psoriatic plaques. 
Therefore, psoriasis is typically classiﬁ  ed as a Th1-driven 
disease. The central role of T cells has been proven many 
years ago because cyclosporin A, a T cell-targeted immune 
suppressive drug, had been found clinically effective in the 
treatment of psoriasis (Mueller and Herrmann 1979). Further 
evidence has come from the transmission of psoriasis by 
bone marrow transplantation (Wahie et al 2006). As a ﬁ  rst 
step, T cells undergo extravasation and subsequent migration 
into the lesion, being recruited by chemotactic and adhesion 
molecule-mediated signals (Schon and Ludwig 2005). 
Then, their functional activation in the affected skin takes 
place, which leads to massive release of proinﬂ  ammatory 
mediators and activation of cytotoxic mechanisms. Thus, 
further T cell-mediated damage to the skin occurs. Expres-
sion of integrin LFA-1 (the leukocyte function-associated 
antigen) on T cell membrane appears to play a central role 
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Figure 1 TNF-α-driven inﬂ  ammatory cascade in the skin. Among the pre-formed 
mediators released by mast cells (A), TNF-α boosts the pro-inﬂ  ammatory activation 
of resident cell populations which include endothelial cells (B). In their turn, endothelial 
cells respond to TNF-α with up-regulated expression of surface adhesion molecules, 
which facilitate the adhesion and migration of leukocytes to peripheral tissues, and 
a new wave of leukocyte-derived cytokine release (C). Eventually, skin keratinocytes 
amplify the inﬂ  ammatory response at the local level, with massive release of cytokines, 
chemokines, and growth factors (D).
Abbreviations: TNF-α, tumor necrosis factor-α.Biologics: Targets & Therapy 2008:2(4) 690
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Figure 2 Strategies for targeted biological therapy of psoriasis. These include existing and potential biological drugs for the therapy of psoriasis, such as anti-TNF-α (A) or 
anti-LFA-1 (B) antibodies, inhibitors of CD2 expression on the surface of activated pathogenic T cells (C), or cytokines to balance the Th1-skewed immune response (D), these 
last presently under investigation.
Abbreviations: APC, antigen-presenting cell; LFA-1, lymphocyte function-associated antigen-1;   TNF-α, tumor necrosis factor-α.
for both T cell extravasation and functional activation. The 
LFA-1 integrin binds to the cognate ligand, the intercellular 
adhesion molecule (ICAM)-1, expressed on the surface of 
the endothelial and epithelial cells as well as on antigen-
presenting cells. This binding maximally activates T cell 
functions (Hogg et al 2003), and it is speciﬁ  cally targeted by 
efalizumab, the humanized monoclonal antibody that binds 
to the CD11a portion of LFA-1 currently used as a relatively 
safe and effective biological drug for the therapy of psoriasis 
(Figure 2B). Another molecular interaction implicated in 
the functional activation of T cells is the binding of the 
costimulatory receptor CD2 on T cell surface, to its ligand 
LFA-3 on antigen-presenting cells. Indeed, the ﬁ  rst biological 
drug approved by the US FDA for the therapy of chronic 
plaque psoriasis was alefacept, a fusion protein formed by 
the binding site of LFA-3 and the constant portion of the 
human IgG, that hence targets and neutralizes the function of 
CD2 (Figure 2C). Finally, the possibility to balance the Th1 
deviation of the immune response with the administration of 
Th2-skewing cytokines is currently under investigation for 
the therapy of psoriasis (Figure 2D).
Clinical results of the use 
of biological drugs in the therapy 
of psoriasis
The biological drugs currently available in Europe with the 
explicit indication to treat psoriasis are etanercept, inﬂ  iximab, 
and efalizumab. The clinical response to therapy in psoriatic 
patients is expressed as a percent of improvement in the 
Psoriasis Area and Severity Index (PASI) score. Other quan-
titative standard parameters employed to describe general 
results of the biological therapies are the Dermatology Life 
Quality Index (DLQI), Physician’s Global Assessment 
(PGA), and the Health-Related Quality-Of-Life (HRQOL) 
(Shikiar et al 2006). Currently, biological therapies are appli-
cable to psoriatic patients with a PASI score 10, a DLQI 
score 10, and a clinical history of lack of response, intol-
erance, or contraindication to standard systemic therapies. Biologics: Targets & Therapy 2008:2(4) 691
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In the paragraphs below, we will overview data on the 
clinical efﬁ  cacy, brieﬂ  y summarized in Table 1, of these 
three biologics administered to the patients with severe-to-
moderate forms of plaque psoriasis. Their safety proﬁ  les 
can be compared in Table 2. The effects of biological drugs 
on the quality of life of psoriatic patients will be discussed 
in detail. While these biological agents may possess greater 
efﬁ  cacy in treating moderate-to-severe psoriasis, there is a 
higher cost associated with their administration compared 
to phototherapy and traditional systemic treatments (Hankin 
et al 2005), with important cost differences for different 
biological drugs (Nelson et al 2008). Furthermore, because 
of the chronic nature of psoriasis, these costs accumulate. 
A deeper analysis showed (Nelson et al 2008) that currently 
recommended treatment regimens for these medications are 
far from being optimal with regard to their cost/efﬁ  cacy ratio. 
The implementation of economic analysis in the phase of 
determining the treatment regimen seems to be essential.
Etanercept
Etanercept is a soluble TNF-α antagonist that competi-
tively inhibits the interaction of TNF-α with cell-surface 
receptors. The impaired interaction with receptors pre-
vents TNF-α-mediated cellular responses and modulates 
the activity of other TNF-α-regulated pro-inﬂ  ammatory 
cytokines. In agreement with the Guidelines of the British 
Association of Dermatologists (BAD), Etanercept is recom-
mended as the anti-TNF agent of choice for patients with 
moderate-to-severe stable psoriasis (Smith et al 2005). The 
drug (etanercept, Enbrel®) was approved by the US FDA 
for the treatment of patients with psoriasis, PsA, rheumatoid 
arthritis (RA), juvenile idiopathic arthritis, and ankylosing 
spondylitis. With regard to psoriasis, the European Agency 
for the Evaluation of Medicinal Products (EMEA) has 
approved etanercept for the treatment of adults with mod-
erate-to-severe psoriasis who failed to respond to, had a 
contraindication to, or were intolerant to other systemic 
therapy, including cyclosporin, methotrexate, or psoralen 
and ultraviolet A (PUVA).
More than an eight years long clinical experience with 
etanercept in the treatment of RA has demonstrated its 
high therapeutic potential, safety, and patients’ compliance 
(Krueger et al 2006). The therapy with etanercept results 
in a substantial improvement in pruritus and health-related 
quality of life parameters. The recommended starting doses 
are injections of 25 mg or 50 mg of etanercept twice a week 
(BIW) for the ﬁ  rst 12 weeks, followed, if necessary, by 25 mg 
BIW. The total duration of etanercept course depends on the 
clinical response of the patient but should not be longer than 
24 weeks. The phase II (Gottlieb et al 2003a) and phase III 
(Leonardi et al 2003; Papp et al 2005) clinical trials, which 
had enrolled more than 1000 patients with moderate-to-severe 
chronic plaque psoriasis, have demonstrated that high starting 
dose of etanercept (50 mg BIW) resulted in the faster onset of 
therapeutic action and the higher efﬁ  cacy rate as compared to 
low starting dose (25 mg BIW). After 12 weeks of treatment, 
34% of patients treated with 25 mg etanercept BIW, achieved 
more than 75% improvement in PASI (PASI-75) compared 
with 49% of those receiving 50 mg BIW. At the cessation of 
the trials (24 weeks), 44% of the patients receiving 25 mg 
etanercept BIW and 59% of the patients who started with 
50 mg etanercept BIW achieved or maintained a PASI-75 
response, respectively (Leonardi et al 2003; Papp et al 2005). 
These data suggested that the initial dose of 50 mg etanercept 
BIW is the optimal therapeutic approach in psoriasis with 
regard to clinical parameters and disease severity (Boehncke 
et al 2006), with a tapering of the therapeutic dosage to 
25 mg BIW after 12 weeks for patients achieving a PASI-75 
Table 1 Short-term efﬁ  cacy of biological drugs in the therapy of psoriasis
Agent Study Dosing Time to primary 
end point
Results (% of patients 
reaching PASI75)
Etanercept Gottlieb et al 2003a 2 × 25 mg weekly SC Week 12 30%
Etanercept Leonardi et al 2003 1 × 25 mg vs 2 × 25 mg vs Week 12 14% vs 34% vs 49%
2 × 50 mg weekly SC
Inﬂ  iximab Chaudhari et al 2001 5 mg/kg vs Week 10 82% vs 73%
10 mg/kg IV at weeks 0, 2 and 6
Inﬂ  iximab Gottlieb et al 2004 3 mg/kg vs Week 10 72% vs 88%
5 mg/kg IV at weeks 0, 2 and 6
Efalizumab Gordon et al 2003 1 mg/kg weekly SC Week 12 27%
Efalizumab Lebwohl et al 2003 1 mg/kg vs 2 mg/kg weekly SC Week 12 22% vs 28%
Efalizumab Menter et al 2005 1 mg/kg weekly SC Week 12 27%Biologics: Targets & Therapy 2008:2(4) 692
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response. A starting dosage of 100 mg of etanercept once 
a week (OW) for 12 weeks has been evaluated in a limited 
clinical study (Cassano et al 2006). In this comparative pilot 
study, 108 patients with plaque psoriasis were enrolled and 
allocated into two experimental groups, one treated with 
50 mg BIW and one with 100 mg OW. After 12 weeks, the 
efﬁ  cacy and tolerability parameters were compared. The 
authors have drawn conclusions that the two dosage regimens 
were similar.
After the 24 week-long course of etanercept therapy, 
the time of the disease relapse ranges from 70 to 91 days 
and appears to be dose-related (Smith et al 2006). In case of 
relapse, the therapy with etanercept can be repeated without 
loss of drug efﬁ  cacy (Gottlieb et al 2003a). Etanercept is 
generally well tolerated and the compliance of the patients 
is quite high. Although laboratory monitoring is not 
mandatory for patients treated with etanercept, thorough 
laboratory tests are strongly recommended before start-
ing the therapy to exclude re-activation of tuberculosis, 
human immunodeﬁ  ciency virus, and hepatitis. There are 
several reports documenting that etanercept may be a 
safe option for treating patients suffering from hepatitis 
C (Magliocco and Gottlieb 2004; Rokhsar et al 2006). An 
accurate patient history is generally sufﬁ  cient to recognize 
other standard limitations for the therapy with etanercept, 
such as demyelinating neurological disorders, malignancy 
and severe congestive heart failure (Boehncke et al 2006). 
In the everyday clinical practice, the most common imme-
diate adverse event is the reaction at the site of injection, 
particularly during the ﬁ  rst month of therapy. Usually, this 
event tends to resolve without any medical intervention. 
In general, etanercept as all the other biologics should 
be prescribed by a dermatologist with vast experience in 
the management of difﬁ  cult-to-treat and resistant forms 
of psoriasis. In our personal experience, we carry out an 
accurate screening program before starting the therapeutic 
course with biological drugs. Thorough monitoring is also 
performed every 6–8 weeks during the treatment period and 
every 12 weeks in the follow-up period.
Inﬂ  iximab
In November 2005, Centocor Inc. announced that the US 
FDA accepted ﬁ  ling of a supplemental Biologics License 
Application (sBLA) for the use of inﬂ  iximab in the treatment 
of moderate-to-severe plaque psoriasis. The acceptance of this 
document followed the September 2005 European Commission 
approval of inﬂ  iximab for the treatment of moderate-to-severe 
plaque psoriasis in adults who failed to respond to, had a 
contraindication to, or were intolerant of other systemic therapy 
including cyclosporin A, methotrexate, or PUVA. The drug has 
been shown effective also in the treatment of erythrodermic 
and pustular psoriasis (Lewis et al 2005).
Table 2 Safety proﬁ  les of the biological agents in the therapy of psoriasis
Agent Common side events Potential serious adverse events
Etanercept 1.  Injection site reaction
2.  Respiratory tract infection
3. Headache
4. Nausea
5. Dizziness
6. Cough
7. Abdominal pain
8. Rash
1. Serious  infections
2.  Pancytopenia and aplastic anemia
3. Demyelinating  disorders
4.  Congestive heart failure or its worsening
5. Auto-antibody formation and lupus-like syndrome
6.  Possible increased risk of malignancy
Inﬂ  iximab 1.  Respiratory tract infections
2. Nausea
3. Abdominal pain
4. Dyspepsia
5. Fever
6. Fatigue
7. Headache
8. Rash
1. Infusion  reaction
2.  Serious infections, including reactivation of latent tuberculosis
3. Demyelinating  disorders
4.  Congestive heart failure or its worsening
5. Autoantibody formation and lupus-like syndrome
6.  Possible increased risk of malignancy
Efalizumab 1.  First dose reaction complex
2. Headache
3. Chills
4. Fever
5. Nausea
6. Myalgia
1. Thrombocytopenia
2. Psoriasis  worsening
3. Rebound  psoriasis
4. Serious  infections
5.  Possible increased risk of malignancy
6. Inﬂ  ammatory arthritis
7. Hypersensitivity  reactionBiologics: Targets & Therapy 2008:2(4) 693
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This biological drug should be prescribed as a 
monotherapy and administered intravenously (iv) at doses 
of 3, 5, or 10 mg/kg three times, at week 0, 2, and 6. This 
protocol results in a rapid and signiﬁ  cant clearance of pso-
riatic lesions as compared to the placebo. At week 10, after 
the three-dose induction regimen, 82% and 73% of patients 
treated with 5 mg/kg and 10 mg/kg, respectively, achieved 
PASI-75. The same PASI-75 was observed in 18% of patients 
in the placebo group. These data were obtained in a small 
phase II, randomized, double-blind clinical trial (Chaudhari 
et al 2001). No signiﬁ  cant differences in the clearing of 
disease were observed between doses of 5 and 10 mg/kg as 
induction regimen, although the dose of 10 mg/kg led to a 
longer remission (Gottlieb et al 2003b). In another phase 
II, randomized, double-blind study, the maximum response 
to inﬂ  iximab was observed at week 10. The percentage of 
patients achieving PASI-75 at this time-point was 72%, 88%, 
and 6% for the groups treated with 3 mg/kg, 5 mg/kg and 
placebo, respectively. This highly positive clinical result was 
maintained until week 14 after discontinuation of therapy in 
the 5 mg/kg group. In the group treated with 3 mg/kg, relapses 
occurred after 10 weeks, suggesting that a maintenance dose 
every 8 weeks should be considered after the initial induction 
regimen (Gottlieb et al 2004). In the extended multicenter 
European Inﬂ  iximab for Psoriasis Efﬁ  cacy and Safety Study 
(EXPRESS), 61% and 45% of patients receiving initial doses 
of 5 mg/kg at weeks 0, 2 and 6 and, then, every 8 weeks, 
achieved PASI-75 and PASI-90, respectively, at week 50. 
These data conﬁ  rmed the efﬁ  cacy of maintenance regimens 
over 1 year in the treatment of moderate-to-severe psoriasis 
(Reich et al 2005). Recently, in order to deﬁ  ne the lowest 
effective inﬂ  iximab dose and the largest interval between 
two consecutive administrations, two maintenance protocols 
(continuous and intermittent) were compared (Menter et al 
2007). Patients were randomized for the induction therapy 
with 3 mg/kg, 5 mg/kg inﬂ  iximab or placebo. All inﬂ  iximab-
treated participants were further randomized at week 14 for 
the continuous or intermittent maintenance regimens with the 
same doses used during the induction period. At week 10, 
70.3% and 37.1% percent of patients treated with 3 mg/kg, 
and 75.5% and 45.2% of patients receiving 5 mg/kg, achieved 
PASI-75 and PASI-90, respectively, versus 1.9% (PASI-75) 
and 0.5% (PASI-90) of patients receiving the placebo. At 
week 50, the PASI responses were better maintained with 
continuous bimonthly therapy than with intermittent, “at 
request” maintenance protocol. The best PASI values were 
achieved in the group treated with 5 mg/kg inﬂ  iximab. The 
safety proﬁ  le in this study was similar to that observed in 
the previous trials. During the induction period, a higher 
incidence of adverse events and infusion reactions in both 
the inﬂ  iximab-treated groups was observed as compared to 
the placebo group. However, an increased incidence of infu-
sion reactions in the 3-mg/kg inﬂ  iximab administered “at 
request” was observed. Two cases of tuberculosis and 2 cases 
of lupus-like syndrome were observed in patients treated 
with inﬂ  iximab, whereas lymphoproliferative disorders or 
demyelinating conditions were not reported.
Different adverse events were observed in clinical trials 
with inﬂ  iximab. The most common were infusion-related 
immediate reactions occurring during, or within 1 hour 
after, intravenous infusion. These included urticaria, fever, 
hypo/hypertension, and very rarely anaphylaxis. Twenty 
percent of patients treated with inﬂ  iximab developed an 
infusion reaction compared with 10% of patients receiving 
the placebo. Thus, a need of antihistamine and antipyretic 
pretreatment before infusion was justiﬁ  ed. Patients positive 
for antiinﬂ  iximab antibodies were more likely to have an 
infusion reaction as compared to those who were negative 
(Menter et al 2005). Like all TNF-α inhibitors, inﬂ  iximab is 
an immunosuppressive agent and hence is associated with the 
occurrence of infections, lupus-like syndrome, demyelinating 
conditions, and a possible increase in lymphoma risk. The 
infections, particularly the reactivation of latent tuberculosis 
and other opportunistic infections, are a major concern in 
patients treated with this biological drug. Indeed, clinical 
trials showed that 36% of patients receiving inﬂ  iximab 
developed infections versus 25% of patients in the placebo 
group (Weinberg 2006). These data conﬁ  rm the necessity for 
rigorous screening of the infection before treatment, includ-
ing a PPD skin test and chest radiographs. In the follow-up 
period, symptoms like persistent fever, weight loss and night 
sweats should be taken into consideration. A prophylaxis of 
latent infections should be done routinely. A meta-analysis 
of rare harmful adverse effects observed in randomized 
trials on the safety of anti-TNF-α therapy has demonstrated 
an increased risk of infections and a dose-dependent risk 
of blood cell, skin, and solid organ tumours (Bongartz et al 
2006). In contrast, the results from the British Society for 
Rheumatology Biologics Register showed that in clinical 
practice, anti-TNF-α therapy did not increase the risk of 
malignancy in the low risk patients (Dziadzio and Smith 
2007). Several cases of exacerbation of demyelinating dis-
eases and heart failure have also been reported. Therefore, the 
patients having an anamnesis of either central or peripheral 
demyelinating disorders and/or congestive heart failure usu-
ally are excluded from the treatment with anti-TNF-α drugs Biologics: Targets & Therapy 2008:2(4) 694
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(Hochberg et at 2005). As adverse effects of anti-TNF-α 
therapy in psoriasis, liver toxicity, or cholestasis have been 
reported. However, some uncertainties regarding these 
associations remained, because psoriatic patients could be 
predisposed to transaminase abnormalities and the majority 
of them were concomitantly treated with hepatotoxic drugs. 
Haematologic disorders such as leukopenia, neutropenia, 
trombocytopenia and pancytopenia could be associated with 
Inﬂ  iximab administration (Zeichner and Lebwohl 2007).
To date, neither increased risk of embryotoxicity nor 
teratogenicity, nor adverse pregnancy outcome (such as 
birth defects, premature birth, and low birth weight) have 
been reported in arthropatic patients treated with anti-TNF 
therapy versus the general population (Skomsvoll et al 2007). 
However, the available data are limited. Until more data are 
available, no ﬁ  rm conclusions can be drawn regarding the 
safety of anti-TNF therapy in pregnancy. Anti-TNF agents 
are not usually used during lactation, although the risk of 
toxicity is probably negligible (Skomsvoll et al 2007).
Efalizumab
The efﬁ  cacy and safety of efalizumab in the treatment of pso-
riasis has been evaluated in numerous studies. The patients 
treated, all adults with moderate to severe plaque psoriasis 
and candidates for systemic therapy, experienced a greater 
improvement in PASI-75 and PASI-50 than the placebo-
treated group. The best clinical results were obtained with 
weekly 1 mg/ml subcutaneous injections of efalizumab. After 
12 weeks of therapy, 59% and 27% of patients achieved 
PASI-50 and PASI-75, respectively. In the placebo group, the 
values of PASI-50 and PASI-75 were observed in the 14% 
and 4% of the patients, respectively. The efalizumab-treated 
group of patients also showed a greater improvement from the 
baseline in the DLQI overall score with respect to the placebo 
group (47% versus 14%). The therapy was well tolerated 
with neither evidence of systemic toxicity, nor increases in 
infection or malignancy (Gordon et al 2003). Another phase 
III randomized double-blind placebo-controlled study has 
shown similar efﬁ  cacy and safety proﬁ  les when the treat-
ment with efalizumab was extended from 12 to 24 weeks 
(Lebwohl et al 2003). The long-term continuous efalizumab 
therapy not only sustained the efﬁ  cacy without increasing 
cumulative and organ toxicity, but also resulted in additional 
clinical improvement, as demonstrated in two other clinical 
trials. In-fact in a phase III randomized double-blind placebo-
controlled trial followed by an open-label study, 26.6% and 
58.5% of patients, achieving PASI-75 and PASI-50 after 
12 weeks therapy with the 1 mg/kg dose, rose to 43% and 
66% after 24 weeks of continued treatment, respectively 
(Menter et al 2005). In a consecutive open-label trial, the 
PASI improvement was maintained throughout the 30-month 
treatment period (Gottlieb et al 2006).
The median time between discontinuation of efalizumab 
and aggravation of psoriasis was 58 days. The efﬁ  cacy and 
safety of a second treatment with efalizumab in patients 
achieving PASI-75 at week 12 showed a mean PASI 
improvement of 62.3% from the study baseline (Sterry et al 
2006). Efalizumab was shown to provide a similar signiﬁ  cant 
clinical improvement in patients where at least one systemic 
therapy had failed or was contraindicated (Dubertret et al 
2006). Efalizumab was generally well tolerated, with simi-
lar incidence and types of adverse events in the treated and 
placebo groups. The most frequent and short-term adverse 
event reported in all these clinical studies was a ﬂ  u-like 
syndrome with fever, nausea, chills, and headache, com-
monly accompanying the ﬁ  rst dose and disappearing by the 
third dose of drug administration. Regarding the incidence of 
infections, no signiﬁ  cant difference between the efalizumab-
treated group (29%) and the placebo-group (26%) was 
shown, and the frequency of infections did not increase with 
the extended therapy up to 27 months. Thorough analysis 
of the clinical trials with efalizumab did not reveal cases of 
re-activation of latent tuberculosis, Pneumocystis carinii, 
histoplasmosis, or toxoplasmosis infections (Langley et al 
2005). Although thrombocytopenia (0.3% of patients treated) 
and hemolytic anemia represented rare adverse events, 
the monitoring of platelet count is recommended. Efali-
zumab does not appear to increase the risk of arthropathy, 
as was shown in the long-term studies up to three years of 
continuous treatment (Pincelli et al 2006). Up to now, there 
are no reports on an increased risk of malignancy in psoria-
sis patients treated with efalizumab. Nonetheless, caution 
is strongly recommended when any immune suppressive 
drug is used.
A rather peculiar exacerbation of psoriasis can occur 
during treatment with efalizumab. In a report by an English 
group (Menter and Grifﬁ  ths 2007), up to 20% of the patients 
developed mild, transient, papular ﬂ  are localized on body folds. 
These skin lesions were easily managed with topical steroids. 
In addition, 5% of nonresponders to the therapy developed 
severe generalized inﬂ  ammatory ﬂ  are within 6–10 weeks, 
which required systemic therapy with methotrexate and/or dis-
continuation of the therapy with efalizumab. Thirteen per cent 
of the patients who stopped the efalizumab therapy abruptly 
developed a rebound syndrome, deﬁ  ned as a 125% increase in 
severity compared with pretreatment baseline, or as a worsening Biologics: Targets & Therapy 2008:2(4) 695
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of the form of psoriasis. It should be stressed that the majority 
of these patients failed to achieve a PASI-50 response after 
12 weeks of efalizumab treatment (Papp 2006).
The Italian experience 
with biological drugs
In order to evaluate the long-term results of the current 
treatments of moderate-to-severe psoriasis, the research 
program PSOCARE was recently promoted by the Italian 
Drug Agency (AIFA). The PSOCARE research program 
aims at the improvement of assistance services for psoriatic 
patients. It evaluates the factors that help to predict responses 
to different systemic treatments, their efﬁ  cacy and safety on 
a large-scale basis. The program co-ordinates and standard-
izes different strategies in the management of psoriasis in 
Italy. The network of various clinical centers involved in 
this program represents a basis for co-ordinated multicenter 
clinical studies on the biological drugs in psoriasis. The 
program is outlined as a cohort study that foresees an active 
three year-long follow-up of all psoriatic patients treated with 
biological drugs or other systemic therapy for 8, 16, 32, 52, 
78, 104, and 208 weeks. All patients who received systemic 
treatment with PUVA, cyclosporin A, acitretin, methotrexate, 
efalizumab, etanercept, or inﬂ  iximab for the ﬁ  rst time, are 
eligible to be included in this program. In the period from 
August 1st 2004 to September 20th 2007, 9,954 subjects 
were included in this program. Later on, 974 patients were 
however excluded from the follow-up, due to insufﬁ  cient 
information on the date and/or type of therapy prescribed. 
The remaining 8,980 subjects (67% males and 33% females, 
mean age 49 years) were analyzed, with 6,547 of them (73%) 
contributing to the follow-up (the total number of visits was 
19,386). The others (2,433 patients, 27%) could not contrib-
ute to the follow-up because they were participating in the 
study for a period shorter than two months. Furthermore, 
1,430 visits (7.4%) were excluded from the follow-up due 
to deviation from the requisites of the program. The patients 
eligible for the PSOCARE program and subjected to com-
plete analysis (n = 4,287) received biological drugs according 
to the following distribution: etanercept (n = 2,392), inﬂ  ix-
imab (n = 770), and efalizumab (n = 1,125). The incidence 
of adverse reactions was similar for all the three biological 
drugs (around the 1%–1.5%). Six cases of death were 
observed: (a) two cases due to cardiac arrest (one in the 
group of etanercept and one in the group of efalizumab); 
(b) one case due to lung embolism (in a patient treated with 
acitretin); (c) one case due to bronchopneumonia in a patient 
with etanercept; (d) one case due to an unspeciﬁ  ed infection 
in a patient with efalizumab; and (e) a case of sepsis from 
Candida crusei in a patient initially treated with etanercept 
and subsequently with efalizumab. The second PSOCARE 
report was published in 2007, and has conﬁ  rmed a slight 
increase of total infectious episodes in the group of patients 
treated with biological drugs (n = 81, 0.74%) in comparison to 
those treated with conventional medicines (n = 36, 0.5%).
Conclusions and perspectives
There are currently four biological drugs approved for 
the treatment of plaque-type psoriasis worldwide, namely 
alefacept, efalizumab, etanercept, and inﬂ  iximab. Only three 
of them, namely etanercept, inﬂ  iximab, and efalizumab, 
are approved by EMEA for the treatment of psoriasis in the 
European Union. The British Association of Dermatology has 
recently published detailed guidelines covering the criteria 
of choice of biological drugs (Smith et al 2005). According 
to these guidelines, efalizumab is preferred for patients with 
a high risk of latent tuberculosis or evidence of demyelinat-
ing diseases. Inﬂ  iximab is recommended when rapid disease 
control is requirered, and etanercept is to be chosen for the 
treatment of stable psoriasis. Taking into consideration the 
lifelong nature of psoriasis, further research is needed to 
evaluate the long-term disease control by these drugs. In 
addition, although numerous clinical trials have provided 
evidence on the safety proﬁ  le of these drugs, their long-term 
side effects are still to be evaluated in patients with psoriasis. 
Finally, there are no comparative data on the clinical efﬁ  cacy 
and safety of the different biological drugs used in the man-
agement of psoriasis so far.
Here we focused on the biological drugs with immune-
speciﬁ  c molecular targets. It is important to note that not 
all patients with moderate-to-severe psoriasis respond to 
these therapies. In some cases, the administration of these 
drugs is even associated to episodes of worsening of the 
disease. These clinical observations indicate that, beyond 
the immune-mediated processes targeted by the biologics, 
other skin-speciﬁ  c mechanisms, undeﬁ  ned so far, may play 
a relevant role in the induction, maintenance, and/or ampli-
ﬁ  cation of this disorder. According with this pathogenetic 
complexity, some psoriatic patients with low response to 
biologic monotherapy may display a relevant improvement 
when treated with biological drugs in combination with 
conventional systemic therapy (Robinson et al 2007). This 
experience is however limited and is not authorized for the 
treatment of psoriasis presently. Conventional systemic drugs 
may better counteract some pathogenetic component taking 
place in the psoriatic epidermis, and hence favor the recovery Biologics: Targets & Therapy 2008:2(4) 696
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of the proliferation/differentiation homeostasis in the skin 
(Schwartz et al 1992; Heenen et al 1998). The crucial con-
tribution of epidermis-speciﬁ  c processes to the pathogenesis 
of psoriasis is however vastly ignored, and certainly needs to 
be investigated to ﬁ  nally clarify the molecular basis of pso-
riasis at the local level and eventually provide new molecular 
targets for future, innovative biological drugs.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
Baumgarth N, Bevins CL. 2007. Skin deep but complex. Nature, 
449:551–3.
Boehncke WH, Brasie RA, Barker J, et al. 2006. Recommendations for the 
use of etanercept in psoriasis: a European dermatology expert group 
consensus. J Eur Acad Dermatol Venereol, 20:988–98.
Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy 
in rheumatoid arthritis and the risk of serious infections and malignan-
cies: systematic review and meta-analysis of rare harmful effects in 
randomized trials. JAMA, 295:2275–85.
Bruch-Gerharz D, Schnorr O, Suschek C, et al. 2003. Arginase 1 over-
expression in psoriasis. Limitation of inducible nitric oxide synthase 
activity as a molecular mechanism for keratinocyte hyperproliferation. 
Am J Pathol, 162:203–11.
Cassano N, Loconsole F, Galluccio A, et al. 2006. Once-weekly administration 
of high-dosage etanercept in patients with plaque psoriasis: results of a pilot 
experience (power study). Int J Immunopathol Pharmacol, 19:823–7.
Chaudhari U, Romano P, Mulcahy LD, et al. 2001 Efﬁ  cacy and safety of 
inﬂ  iximab monotherapy for plaque-type psoriasis: a randomized trial. 
Lancet, 9271:1842–47.
Dziadzio M, Smith R. 2007. Meta-analysis is no substitute for a compre-
hensive national registry. Clin Rheumatol, 26:1134–5.
Dubertret L, Sterry W, Bos JD, et al. 2006. Clinical experience acquired 
with the efalizumab (Raptiva) (CLEAR) trial in patients with moder-
ate-to-severe plaque psoriasis: results from a phase III international 
randomized, placebo-controlled trial. Br J Dermatol, 155:170–81.
Girolomoni G, Pastore S, Albanesi C, et al. 2002. Targeting tumor necrosis 
factor-α as a potential therapy in skin inﬂ  ammatory skin diseases. Curr 
Opin Investig Drugs, 3:1590–5.
Gisondi P, Gubinelli E, Cocuroccia B, et al. 2004. Targeting tumor necrosis 
factor-α in the therapy of psoriasis. Curr Drug Targets Inﬂ  amm Allergy, 
3:175–83.
Gordon KB, Papp KA, Hamilton TK, et al. 2003. Efalizumab for patients 
with moderate to severe plaque psoriasis: a randomized controlled trial. 
JAMA, 290:3133–5.
Gordon KB, West DT. 2001. Biologic therapy in psoriasis. In: 
Wolverton S (ed). Comprehensive dermatologic drug therapy. 
Philadelphia, PA: WB Saunders Co, pp. 928–42.
Gottlieb AB, Matheson RT, Lowe N, et al. 2003a. A randomized trial of etan-
ercept as monotherapy for psoriasis. Arch Dermatol, 139:1627–32.
Gottlieb AB, Chaudhari U, Mulcahy LD, et al. 2003b. Inﬂ  iximab mono-
therapy provides rapid and sustained beneﬁ  t for plaque-type psoriasis. 
J Am Acad Dermatol, 48:829–35.
Gottlieb AB, Evans R, Li S, et al. 2004. Inﬂ  iximab induction therapy for 
patients with severe plaque-type psoriasis: a randomized double-blind, 
placebo-controlled trial. J Am Acad Dermatol, 51:534–42.
Gottlieb AB, Hamilton T, Caro I, et al. 2006. Efalizumab Study Group. 
Long-term continuous efalizumab therapy in patients with moderate to 
severe chronic plaque psoriasis. J Am Acad Dermatol, 54:5154–63.
Grifﬁ  ths CEM, Barker JNWN. 2007. Pathogenesis and clinical features of 
psoriasis. Lancet, 370:263–71.
Hankin CS, Feldman SR, Szczotka A, et al. 2005. A cost comparison of 
treatments for moderate to severe psoriasis. Drug Ben Trends, 17:200–14.
Heenen M, Laporte M, Noel JC, et al. 1998. Methotrexate induces 
apoptotic cell death in human keratinocytes. Arch Dermatol Res, 
290:240–5.
Hochberg MC, Lebwohl MG, Plevy SE, et al. 2005. The beneﬁ  t/risk proﬁ  le 
of TNF-blocking agents: ﬁ  ndings of a consensus panel. Semin Arthritis 
Rheum, 34:819–36.
Hogg N, Laschinger M, Giles K, et al. 2003. T cell integrins: more than just 
sticking points. J Cell Sci, 116:4695–705.
Krueger G, Elewski B, Papp K, et al. 2006. Patients with psoriasis respond 
to continuous open-label Etanercept treatment after initial incomplete 
response in randomized, placebo controlled trial. J Am Acad Dermatol, 
54:S112–9.
Lande R, Gregorio J, Facchinetti V, et al. 2007. Plasmacytoid dendritic 
cells sense self-DNA coupled with antimicrobial peptide. Nature, 
449:564–9.
Langley RG, Carey WP, Rafal ES, et al. 2005. Incidence of infection during 
efalizumab therapy for psoriasis: analysis of the clinical trial experience. 
Clin Ther, 27:1317–28.
Lebwohl M, Tyring SK, Hamilton TK, et al.; Efalizumab Study Group. 2003. 
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. 
N Engl J Med, 349:2004–13.
Leonardi CL, Powers JL, Matheson RT, et al. 2003. Etanercept as mono-
therapy in patients with psoriasis. N Engl J Med, 349:2014–22.
Lewis TG, Tuchinda HW, Lim HKW. 2005. Life-threatening pustolar and 
erythrodermic psoriasis responding to inﬂ  iximab. J Drugs Dermatol, 
5:546–8.
Liu Y, Krueger JG, Bowcock AM. 2007. Psoriasis: genetic associations and 
immune system changes. Genes Immun, 8:1–12.
Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor 
superfamilies: integrating mammalian biology. Cell, 104:487–501.
Magliocco MA, Gottlieb AB. 2004. Etanercept therapy for patients with 
psoriatic arthritis and concurrent hepatitis C virus infection: report of 
three cases. J Am Acad Dermatol, 51:580–4.
Menter A, Gordon K, Carey W, et al. 2005. Efﬁ  cacy and safety observed 
during 24 weeks of efalizumab therapy in patients with moderate to 
severe plaque psoriasis. Arch Dermatol, 141:31–8.
Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomized com-
parison of continuous vs. intermittent inﬂ  iximab mainenance regimens 
over 1 year in the treatment of moderate-to-severe plaque psoriasis. 
J Am Acad Dermatol, 56:31–44.
Menter A, Grifﬁ  ths CE. 2007. Current and future management of psoriasis. 
Lancet, 370:272–84.
Mueller W, Herrmann B. 1979. Cyclosporin A for psoriasis. N Engl J Med, 
301:555.
Nelson AA, Pearce DJ, Fleischer AB, et al. 2008. Cost-effectiveness of 
biological treatments for psoriasis based on subjective and objective 
efﬁ  cacy measures assessed over a 12-week treatment period. J Am 
Acad Dermatol, 58:125–5.
Ong PY, Ohtake T, Brandt C, et al. 2002. Endogenous antimicrobial peptides 
and skin infections in atopic dermatitis. N Engl J Med, 347:1151–60.
Papp KA, Tyring S, Lahfa M, et al. 2005. A global phase III randomized 
controlled trial of etanercept in psoriasis: safety, efﬁ  cacy, and effect 
of dose reduction. Br J Dermatol, 152:1304–12.
Papp KA. 2006. The long-term efﬁ  cacy and safety of new biological thera-
pies for psoriasis. Arch Dermatol Res, 298:7–15.
Pasparakis M, Curtois G, Hafner M, et al. 2002. TNF-mediated inﬂ  amma-
tory skin disease in mice with epidermis-speciﬁ  c deletion of IKK2. 
Nature, 417:861–6.
Pastore S, Mascia F, Mariani V, et al. 2006. Keratinocytes in skin inﬂ  am-
mation. Expert Rev Dermatol, 1:279–91.
Pincelli C, Henninger E, Casset-Semanaz F. 2006. The incidence of 
arthropathy adverse events in efalizumab-treated patients is low and 
similar to placebo and does not increase with long-term treatment: 
pooled analysis of data from Phase III clinical trials of efalizumab. 
Arch Dermatol Res, 298:329–38.Biologics: Targets & Therapy 2008:2(4) 697
Biologics in psoriasis
Reich K, Nestle FO, Papp K, et al. 2005. EXPRESS study investigators. 
Inﬂ  iximab induction and maintenance therapy for moderate-to-severe 
psoriasis: a phase III, multicentre, double-blind trial. Lancet, 
366:1367–74.
Robinson MR, Korman BD, Korman NJ. 2007. Combination immunosup-
pressive therapies. Arch Dermatol, 143:1053–7.
Rokhsar C, Rabhan N, Cohen SR. 2006. Etanercept monotherapy for a 
patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C 
infection. J Am Acad Dermatol, 54:361–2.
Schon MP, Ludwig RJ. 2005. Lymphocyte trafﬁ  cking to inﬂ  amed skin. 
Molecular mechanisms and implications for therapeutic target 
molecules. Expert Opin Ther Targets, 9:225–43.
Schwartz PM, Barnett SK, Attillasoy ES, et al. 1992. Methotrexate induces 
differentiation of human keratinocytes. Proc Natl Acad Sci U S A, 
89:594–8.
Shikiar R, Willian MK, Okun MM, et al. 2006. The validity and respon-
siveness of three quality of life measures in the assessment of psoriasis 
patients: results of a phase II study. Health Qual Life Outcomes, 4:71.
Skomsvoll JF, Wallenius M, Koksvik HS, el al. 2007. Drug Insight: anti-
tumor necrosis factor therapy for inﬂ  ammatory arthropathies during 
reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol, 
3:156–64.
Smith CH, Anstey AV, Barker JNWN, et al. 2005. British Association 
of Dermatology Guidelines for the use of biological interventions in 
psoriasis 2005. Br J Dermatol, 153:486–97.
Sterry W, Stingl G, Langley RG, et al.; CLEAR Multinational Study Group. 
2006. Clinical Experience Acquired with Raptiva (CLEAR) trial in 
patients with moderate-to-severe plaque psoriasis: results from extended 
treatment in an international, Phase III, placebo-controlled trial. J Dtsch 
Dermatol Ges, 4:947–56.
Travers JB. 2000. Novel immunomodulators for topical skin disease therapy. 
Expert Opin Invest Drugs, 9:529–42.
Valdimarsson H. 2007. The genetic basis of psoriasis. Clin Dermatol, 
25:563–7.
Wahie S, Alexandruff A, Reynolds NJ, et al. 2006. Psoriasis occurring 
after myeloablative therapy and autologous stem cell transplantation. 
Br J Dermatol, 154:194–5.
Weinberg JM. 2006. A review of the safety of the tumor necrosis inhibitors 
inﬂ  iximab, etanercept, and adalimumab. In: Weinberg JM, Buchholz R, 
(Eds). TNF-alpha inhibitors. Basel: Birkhäuser, pp. 115–27.
Zeichner JA, Lebwohl M. 2007. Potential complications associated with the 
use of biologic agents for psoriasis. Dermatol Clin, 25:207–13.